Tuberculosis in Europe is declining in countries in western and central Europe, but the burden is still high and increasing in eastern Europe. HIV/AIDS is increasing dramatically in eastern Europe. HIV-related tuberculosis (TB/HIV) morbidity and mortality are expected to accelerate significantly in the future.
Introduction
The World Health Organization (WHO) declared tuberculosis (TB) to be a global emergency in 1993 (1) and formulated the DOTS strategy to control TB in 1994 (2) . More recently, WHO published an expanded framework for effective TB control that covers the technical, managerial, social and political dimensions (3) . By 2002, 155 countries were implementing the DOTS strategy (4) . However, only 33% of global TB cases were reported to be covered by DOTS in 2001, with considerable variation between regions. The European Region of WHO reported 13% DOTS population coverage, the lowest among the WHO regions. TB and HIV/AIDS are global public health problems with considerable mutual interaction. Globally, TB is a leading killer of PLWHA. HIV is the most potent force driving the TB epidemic in countries with a high prevalence of HIV. Given the close interaction between the TB and HIV epidemics, the global Stop TB Partnership (http://www.stoptb.org) established the TB/HIV Working Group in 2001 to coordinate and promote interventions to decrease the burden of HIV-related TB (TB/HIV). The Working Group developed a global TB/HIV strategic framework (7) and supportive guidelines for implementation (8) This framework aims to guide European countries in developing their national plan for reducing TB/HIV morbidity and mortality. It builds on strategies developed globally and in Europe for TB control (3, 12, 13) and for HIV/AIDS prevention and care (14) . It sets out the rationale for effective action to address TB/HIV, including the collaboration between national national HIV/AIDS programmes and national TB programmes. It identifies the populations at risk of TB and HIV and the strategic components and key operations required. The main target audience consists of policy-makers in ministries (especially ministries responsible for health, justice and the interior), international agencies and nongovernmental organizations (NGOs).
WHO will revise this framework in the future as further evidence becomes available to inform policy and practice related to TB/HIV. Readers are kindly invited to contact the WHO Regional Office for Europe with their views and comments.
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Background

Links between TB and HIV
HIV can fuel the TB epidemic in several ways (15, 16) . HIV is the most potent known risk factor for progression to active TB in people with latent Mycobacterium tuberculosis infection. HIV also increases the rate of recurrent TB, either from endogenous reactivation or exogenous reinfection. Increasing TB cases among PLWHA enhances the risk of TB transmission to the general community, whether or not they are HIV infected. The level of immunodeficiency at which PLWHA usually develop TB is associated with higher case-fatality rates.
TB may adversely affect the natural history of AIDS in co-infected people, by stimulating HIV replication directly by M. tuberculosis and its cellular components and/or indirectly by releasing cytokines (17, 18) . However, evidence for this is mainly based on studies in vitro (19) and is not yet conclusive in epidemiological studies.
Epidemiology
WHO estimated that there were 484 000 new TB cases in Europe in 2001, representing 6% of the global TB burden. The Russian Federation had the ninth highest burden of TB in the world. Within Europe, the TB incidence varies enormously, from 5 per 100 000 population in Sweden to 181 per 100 000 population in Kazakhstan (4). The female-male ratio was 0.4 among new pulmonary TB cases with a positive sputum smear. This may require research on gender inequality in accessing TB services in some settings (20) . 3. Aim, guiding principles and targets
Aim
The aim of this framework is to assist European countries in planning and implementing TB/HIV interventions jointly by national HIV/AIDS programmes and national TB programmes, with the objective of reducing HIV-related TB morbidity and mortality and minimizing the effects on individual people and on societies.
Guiding principles
This framework is based on the following guiding principles.
Controlling TB/HIV requires implementing a range of interventions including those directly against TB and those directly against HIV (and therefore indirectly against TB).
National HIV/AIDS programmes and national TB programmes should receive the necessary support to fully implement their respective strategies for preventing HIV/AIDS and providing care and support and for controlling TB according to internationally recommended standards.
National HIV/AIDS programmes and national TB programmes should collaborate to ensure that people with HIV/AIDS and people with TB receive a continuum of high-quality care.
Access to TB/HIV services is a human right; it should be protected by confidentiality, should be equitable and should exclude discrimination, including that based on stigma or gender.
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Targets
There are internationally agreed global targets for TB and for HIV but not yet specifically for HIV-related TB. The World Health Assembly passed a resolution in 2000 urging that at least 70% of all new infectious TB cases be detected and that at least 85% of those detected be cured by 2005 (25) . The Millennium Development Goals adopted at the Millennium Summit in September 2000 include the following targets: "to have halted by 2015 and begun to reverse the spread of HIV" and "to have halted by 2015 and begun to reverse the incidence of TB" (26) . The TB/HIV Working Group is presently working to define global and regional targets for TB/HIV and monitoring indicators.
Priorities for TB/HIV in Europe
Setting priorities among countries
Countries in Europe face diverse challenges in responding to TB/HIV. The 52 countries vary considerably in the epidemiological burdens of HIV and TB and the type and quantities of new activities needed to provide the internationally recommended TB and HIV/AIDS services. A country with a high case load, an increasing epidemiological trend and inadequate resources and/or inadequate health system represents a priority for intervention.
Using the above criteria, the sexually transmitted infections (STI)/HIV/AIDS programme and the TB control programme of the WHO Regional Office for Europe have set priorities among European countries according to the need for HIV/AIDS prevention and control (27) and TB control (28) in the next 5 years. Table 1 further groups countries with a combined perspective for priority intervention. The countries with high needs for both HIV/AIDS prevention and control and TB control are also those with the highest need to address TB/HIV. Health care users and health workers often have greater risk of being exposed to M. tuberculosis (35) . TB is most likely to be nosocomially transmitted from people with unrecognized pulmonary TB who have not started any anti-TB treatment and have not been isolated (36) . The emergence of multidrug-resistant TB, often combined with HIV infection, confronts the health care community with unique challenges. Nosocomial TB transmission among HIVinfected patients in Europe has caused outbreaks with high casefatality rates. HIV-infected people have a high attack rate and a shortened incubation period for TB and are susceptible to reinfection, including reinfection with drug-resistant strains.
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Strategic components
The strategic framework to reduce the burden of TB/HIV in Europe is based on the collaboration of national HIV/AIDS programmes and national TB programmes in promoting five components: political commitment, collaborative prevention, intensified case-finding, coordinated treatment and strengthened surveillance. The collaboration of national HIV/AIDS programmes and national TB programmes is based on the guiding principles outlined in section 3.
5.1
Political commitment is needed to promote full implementation of the strategies for HIV/AIDS prevention and control, for TB control and for the programmes collaborative efforts to tackle TB/HIV. Establishing a national high-level committee may promote coordination, intrasectoral and intersectoral collaboration and additional political and financial support. Existing international initiatives should be utilized to foster government commitment and provide additional resources, such as the Stop TB Partnership and the Global Fund to Fight AIDS, Tuberculosis and Malaria (http://www. globalfundatm.org).
5.2
Collaborative prevention for TB and HIV transmission. The core responsibilities of the national HIV/AIDS programme for HIV/AIDS prevention include promoting safer sex and safer injecting drug use, treating STI, screening blood for HIV, implementing universal precautions, providing prophylaxis to prevent mother-to-child transmission (MTCT) of HIV and diagnosing HIV infection early. All these interventions can reduce HIV transmission, thereby contributing to a declining burden of TB/HIV. The core responsibility of the national TB programme is to fully implement the international strategy for controlling TB. Three specific preventive interventions are recommended for collaborative action by national HIV/AIDS programmes and national TB programmes: Isoniazid preventive therapy, environmental measures and postexposure prophylaxis.
5.2.1 Isoniazid preventive therapy (IPT) should be administered to PLWHA with a positive tuberculin skin test. This decreases the risk that recent M. tuberculosis infection progresses and that latent infection is reactivated (37, 38) . Two important requirements are to exclude active TB and to ensure adherence to treatment (39) . The widely used 6-month course is based on a cost-effectiveness study (40, 41) . Extending to 9 months might be considered to maximize the efficacy of IPT, depending on local conditions (42, 43) . Further evidence is necessary to guide IPT where isoniazid resistance is common (43). 
5.5
Strengthened surveillance is critical in controlling TB (49, 50) and HIV/AIDS (51, 52) . Effective surveillance provides data that can be used to develop evidence-based policy, to monitor programmes and to evaluate impact. An effective surveillance system should be able to identify the number and proportion of PLWHA who have TB, the number and proportion of TB patients who are HIV-positive, the risk factors associated with TB/HIV infection, the gender differences, the modalities and outcome of care (53, 54) and the level of drug resistance (55) . Surveillance systems for TB and HIV/AIDS should be sufficiently integrated to be able to perform these functions. Effective methods of linking data on TB and HIV/AIDS must preserve people's right to confidentiality (56). Notification of HIV together with notification of the same person for other diseases should maintain confidentiality.
Key operations
To successfully promote the five strategic components in tackling TB/HIV, the national HIV/AIDS programmes and national TB programmes should jointly ensure eight key operations: central coordination, policy development, surveillance, training, supply EUR/03/5037600 page 11 management, service delivery, health promotion and research. Each country should determine the most effective way of implementing these key operations, depending on the burden of TB/HIV, the organization of the health system and the availability of resources. The full involvement and participation of PLWHA and of TB patients in designing, planning, implementing and evaluating TB/HIV interventions is crucial.
6.1
Central coordination through a national TB/HIV coordinating committee enables national HIV/AIDS programmes and national TB programmes to jointly plan, implement, monitor and evaluate TB/HIV interventions. The committee should include managers from central and peripheral levels of relevant ministries (such as those responsible for health, the interior and justice) and civil society representatives (such as from patients' organizations, other NGOs and the private sector).
6.2
Policy development supports the effective coordination of and collaboration on TB/HIV interventions. The main areas of work include: i) developing policies that promote closer collaboration between national HIV/AIDS programmes and national TB programmes; ii) reviewing the guidelines of national HIV/AIDS programmes and national TB programmes to ensure that they include TB/HIV; iii) developing national protocols and standards for good clinical practice, including ethics and confidentiality; iv) developing partnership with stakeholders, including NGOs (such as patients' organizations and charitable organizations) and private enterprises; v) establishing referral systems between the services of national HIV/AIDS programmes and national TB programmes. An advisory group should develop national TB/HIV policies and guidelines. Such a group should include epidemiologists, public health officials and representatives of the ministry of health, other relevant ministries, NGOs and other partners such as specialized HIV/AIDS and drug control agencies.
6.3
Surveillance is critical for monitoring progress in implementing TB/HIV interventions (such as using population-based outcome measures) and evaluating progress towards achieving targets. Annex 2 lists specific TB/HIV EUR/03/5037600 page 12
indicators that national HIV/AIDS programmes and national TB programmes can use, which may require revising forms and registers to collect data. The national HIV/AIDS programmes and national TB programmes should collaborate in sharing data while preserving patient confidentiality. Patient referral should be properly documented. Collecting and analysing data by gender and age helps to clarify the magnitude and nature of gender disparities and to inform prevention and care programmes. National and regional surveillance reports on HIV/AIDS should include TB as a priority HIV-related disease, and reports on TB should include HIV as an important factor that fuels TB.
6.4
Training on the job should be planned for personnel and other service providers (such as volunteers) to increase and update knowledge on the transmission, prevention and care of HIV/AIDS, TB and TB/HIV. It should also cover universal precautions against HIV and preventing HIV and TB transmission in special settings (such as hospitals, drug dependence treatment services and prisons). Training on how to communicate effectively with patients is also important, especially considering barriers resulting from stigma and social differences. Collaboration between universities, training institutions, professional societies and NGOs is important in developing graduate and postgraduate education and training for health staff involved in HIV/AIDS and TB programmes.
6.5
Supply management is essential to ensure an uninterrupted supply of high-quality anti-TB drugs. This enables TB patients to receive an uninterrupted course of effective treatment and reduces the risk of drug resistance. The same applies to effective IPT. When PLWHA are screened for TB by non-TB services, this should be supported by at least adequate supplies for collecting sputum smears and shipping the samples. Supply management is also a key issue for national HIV/AIDS programmes in scaling up ART to reach the target of 3 million PLWHA by 2005. The availability of ARV drugs may promote uptake of VCT. The national HIV/AIDS programmes and national TB programmes need to collaborate in providing PLWHA who have TB with ART, whether in TB or in infectious disease or HIV facilities. The EUR/03/5037600 page 13
Global TB Drug Facility (GDF) provides a good model for procuring, controlling the quality of and distributing antiretroviral drugs.
6.6
Service delivery involves clarifying the professional and administrative responsibilities necessary to provide six priority collaborative services between the national TB programmes and national HIV/AIDS programmes (Annex 3): i) making available VCT for all TB patients; ii) referring TB patients who are found to be HIV-positive for lifelong HIV support, care and treatment; iii) detecting and treating TB among PLWHA; iv) ensuring IPT treatment to PLWHA who are infected with TB but found not to have active TB; v) applying universal HIV precautions and environmental TB measures for health care workers and users; vi) making available PEP for everyone exposed to HIV.
These collaborative services are part of an HIV/AIDS essential package that includes interventions against HIV (and therefore indirectly against TB) and interventions directly against TB. Services can be delivered at home and at the primary, secondary and tertiary levels of care. Service delivery in each country should be planned based on the epidemiology of TB/HIV, the organization of the health system and the resources available. NGOs may be key partners in serving populations at high risk of HIV and TB. As many PLWHA are injecting drug users, drug dependence treatment services should be also considered for delivering TB/HIV services. Services at the community level include community support for PLWHA and for TB patients to ensure that they adhere to treatment. Primary care services include VCT, IPT and TB treatment. The national HIV/AIDS programmes and national TB programmes should collaborate in exploring the possibility of jointly organizing DOT for anti-TB treatment and introducing ART. Universal HIV precautions and environmental TB measures should be also considered from primary care level. Secondary care services include diagnosing and treating common HIV-related diseases, including pulmonary and extrapulmonary TB (diagnosis usually requires such investigations as smear microscopy, radiography, biopsy and culture). PEP against 
MAIN DEFINITIONS
Countries in Europe with a low TB incidence: European countries with an annual notified incidence rate of less than 20 cases (all types of TB) per 100 000 population.
Directly observed treatment (DOT):
A trained and supervised person observes the person swallowing the drugs. This is part of a range of measures to support people with TB and promote adherence to treatment.
The DOTS strategy: The recommended strategy for TB control that is expanded to apply to both HIV-related and drug-resistant forms of TB. It includes five elements: i) sustained political commitment to increase human and financial resources and make TB control a nationwide activity integral to a national health system; ii) access to quality-assured sputum microscopy for detecting cases of TB among people presenting with, or found through screening to have, symptoms of TB (most importantly, prolonged cough), with special attention to detecting cases among HIV-infected people and other high-risk groups, such as people living in institutions; iii) standardized shortcourse chemotherapy for all cases of TB under proper casemanagement conditions through technically sound and socially supportive treatment services, including direct observation of treatment; iv) an uninterrupted supply of quality-assured drugs with reliable systems of drug procurement and distribution; v) a recording and reporting system enabling outcome assessment of each and every patient and assessment of the overall performance of the programme.
Elimination of TB:
Annual incidence of sputum smear-positive TB less than 1 case per million population or prevalence of infection with M. tuberculosis below 1% and declining.
Harm reduction: Policies or programmes that focus on reducing the harm resulting from the use of drugs (58) . The term is used especially for policies and programmes that aim to reduce harm without necessarily affecting the underlying drug use and requiring abstention from drug use. Examples include needle and syringe exchange and distribution programmes to counteract needle-sharing among injecting EUR/03/5037600 page 16 drug users and treatment of sexually transmitted infections among injecting drug users. However, harm reduction approaches are often the first step towards the eventual cessation of drug use.
Highly active antiretroviral therapy (HAART):
Treatment based on multiple drugs, including a combination of protease inhibitors, nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors.
HIV epidemic levels: i) low level -HIV prevalence has not consistently exceeded 5% in any defined subpopulation; ii) concentrated -HIV prevalence consistently exceeding 5% in at least one defined subpopulation but below 1% in pregnant women in urban areas; iii) generalized -HIV prevalence consistently exceeding 1% in pregnant women.
Population at high risk of TB: Population with an annual notification rate of 100 cases or more (any type of TB) per 100 000 population.
Voluntary counselling and testing (VCT):
Services providing pretest counselling, testing for HIV infection and post-test counselling for anyone wanting to know their HIV status. Management Information System (MIS) 5 Referring to any implementation setting, such as administrative (district), geographical (settlement), health facility or high-risk population.
6
PLWHA needing IPT are those with a positive tuberculin skin test who have had active TB ruled out. 7 Referring to any setting previously identified in which HIV-infected people are routinely brought together. 8 Environmental measures for TB as defined by the national TB programme. 9 Serosurveillance with unlinked anonymous HIV testing. See also the relevant guidelines (46) . 10 These may target high-risk behaviour, environments or communities.
